Loeb Partners’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
Other funds holding NVCR
DCP
Loeb Partners's NVCR Position: Q2 2019 in Review
Loeb Partners sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 200 shares — an estimated $10K sold.
Loeb Partners first reported a position in NVCR in Q4 2018 and held it in 2 quarters. The position peaked at $10K in Q1 2019. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.
- Loeb Partners reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
- Loeb Partners sold 200 NovoCure shares in Q2 2019, an estimated $10K.
- Loeb Partners first reported a position in NovoCure in Q4 2018 and held it in 2 quarters.
- Loeb Partners's NovoCure position peaked at $10K in Q1 2019.
- 197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.
Based on Loeb Partners's 13F filing for Q2 2019.